Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.47 USD | +8.44% | -23.10% | +132.77% |
05-02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 390K 534K | Sales 2025 * | 66.67K 91.25K | Capitalization | 143M 196M |
---|---|---|---|---|---|
Net income 2024 * | -45M -61.59M | Net income 2025 * | -57M -78.01M | EV / Sales 2024 * | 367 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,146 x |
P/E ratio 2024 * |
-3.27
x | P/E ratio 2025 * |
-3.02
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 day | +8.44% | ||
1 week | -23.10% | ||
Current month | -20.99% | ||
1 month | -39.13% | ||
3 months | +90.33% | ||
6 months | +251.32% | ||
Current year | +132.77% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 3.441 | +7.52% | 446 097 |
24-05-08 | 3.2 | -3.32% | 486,934 |
24-05-07 | 3.31 | -4.34% | 610,337 |
24-05-06 | 3.46 | -1.70% | 1,714,356 |
24-05-03 | 3.52 | -21.43% | 2,160,660 |
Delayed Quote Nasdaq, May 09, 2024 at 02:01 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+132.77% | 143M | |
+24.75% | 46.71B | |
+48.83% | 41.8B | |
-1.05% | 41.52B | |
-5.86% | 29.55B | |
+10.93% | 25.78B | |
-20.51% | 19.26B | |
+2.35% | 12.14B | |
-3.26% | 12.08B | |
+28.38% | 11.98B |
- Stock Market
- Equities
- CRDF Stock